JP2008500963A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500963A5
JP2008500963A5 JP2007503063A JP2007503063A JP2008500963A5 JP 2008500963 A5 JP2008500963 A5 JP 2008500963A5 JP 2007503063 A JP2007503063 A JP 2007503063A JP 2007503063 A JP2007503063 A JP 2007503063A JP 2008500963 A5 JP2008500963 A5 JP 2008500963A5
Authority
JP
Japan
Prior art keywords
hiv
antigen
mixed
immunomodulatory oligonucleotide
tcttrctgtct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/008238 external-priority patent/WO2005089231A2/en
Publication of JP2008500963A publication Critical patent/JP2008500963A/ja
Publication of JP2008500963A5 publication Critical patent/JP2008500963A5/ja
Pending legal-status Critical Current

Links

JP2007503063A 2004-03-12 2005-03-11 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性 Pending JP2008500963A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55287104P 2004-03-12 2004-03-12
PCT/US2005/008238 WO2005089231A2 (en) 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Publications (2)

Publication Number Publication Date
JP2008500963A JP2008500963A (ja) 2008-01-17
JP2008500963A5 true JP2008500963A5 (cg-RX-API-DMAC7.html) 2008-05-15

Family

ID=34994209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503063A Pending JP2008500963A (ja) 2004-03-12 2005-03-11 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたhivワクチン活性

Country Status (7)

Country Link
US (1) US20050266015A1 (cg-RX-API-DMAC7.html)
EP (1) EP1729802A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008500963A (cg-RX-API-DMAC7.html)
CN (1) CN101217973A (cg-RX-API-DMAC7.html)
AU (1) AU2005222909B2 (cg-RX-API-DMAC7.html)
CA (1) CA2557443A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005089231A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
JP4726630B2 (ja) * 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
OA13246A (en) * 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.

Similar Documents

Publication Publication Date Title
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
JP2006316072A5 (cg-RX-API-DMAC7.html)
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2007062107A3 (en) Immunostimulatory oligoribonucleotides
EP1766096A4 (en) SIV AND HIV VACCINATION WITH RHCMV AND HCMV BASED IMPFECTORS
JP2005237328A5 (cg-RX-API-DMAC7.html)
JP2009539965A5 (cg-RX-API-DMAC7.html)
JP2003503454A5 (cg-RX-API-DMAC7.html)
RU2007127993A (ru) Сахарид-конъюгатные вакцины
CA2321523A1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
JP2003526662A5 (cg-RX-API-DMAC7.html)
JP2007533729A5 (cg-RX-API-DMAC7.html)
RU2013119946A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
EP2302059A8 (en) Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
EA201101432A1 (ru) Активный фармацевтический ингредиент, адсорбированный на твердой подложке
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
JP2022521410A5 (cg-RX-API-DMAC7.html)
JP2009514840A5 (cg-RX-API-DMAC7.html)
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
WO2005021726A3 (en) Immunogenic hiv compositions and related methods
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
JP2009514527A5 (cg-RX-API-DMAC7.html)
JP2007505923A5 (cg-RX-API-DMAC7.html)
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide